Lancet:巴基斯坦冲突后妇女群体心理干预的有效性:单盲、聚类、随机对照试验

2019-04-03 不详 网络

<span style="font-family:宋体;mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:宋体;mso-fareast-theme-font: minor-fareast;mso-hansi-font-family:Calibri;mso-hansi-t

在低收入和中等收入国家,许多妇女在武装冲突后受到焦虑和抑郁的影响,但几乎没有可扩展的精神卫生保健选择。我们的目标是在巴基斯坦斯瓦特农村受冲突影响的环境中为妇女建立一个简短的群体心理干预的有效性。

在一项单盲、分组、随机、对照试验中,采用分组置换法,以1:1的比例对巴基斯坦斯瓦特乡村地区两个联合委员会的34个社区群进行随机分组。在分配中,对负责确定参与者、获得同意、登记和结果评估的研究人员采取单盲。社区集群是由一名女卫生工作者负责的大约150个家庭组成的社区。招募了年龄在18-60岁之间的妇女,她们提供书面知情同意书,居住在参与的群集集水区,在一般健康问卷(12)中得分至少3分,在世卫组织残疾评估时间表中得分至少17分。采用医院焦虑抑郁量表(HADS)对干预3个月后的主要结果(焦虑和抑郁症状)进行测量。改进的意向治疗分析是使用混合模型进行调整的协变量和集群定义的先验。该试验在澳大利亚新西兰临床试验注册中心(编号12616000037404)注册,现在不对新参与者开放。

研究发现,在2016111日至2016821日期间,从34个符合条件的社区群体中,纳入干预组306名女性和强化常规护理(EUC)306名女性,干预组中288名(94%)的结果和EUC290名(95%)被纳入主要终点分析。3个月时,干预组妇女的HADS平均总分明显低于对照组(10·01 [SD 7·54]vs 14·75[8·11];调整后的平均差[AMD] - 4·53,95% CI - 7·13- 1·92;p = 0·0007)。干预组个体HADS焦虑评分也明显低于对照组(5·43 [SD 4·18]vs 8·02[4·69];AMD - 2·52,95% CI - 4·04- 1·01,抑郁评分(4·59[3·87]vs . 6·73[3·91]);AMD - 2·04- 3·19 - 0·88)。两组均无不良事件报告。

本研究小组心理干预在3个月的临床治疗中显著减少了焦虑和抑郁症状,可能是冲突后心理困扰妇女的一个可行和有效的选择。

原始出处:

Prof Atif Rahman, PhD. Effectiveness of a brief group psychological intervention for women in a post-conflict setting in Pakistan: a single-blind, cluster, randomised controlled trial

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2020-02-03 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2020-01-30 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2019-09-03 xjy13
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1775456, encodeId=8aee1e7545622, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Feb 03 08:33:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724780, encodeId=d24c1e2478062, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Mon Dec 23 19:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830009, encodeId=57d718300090d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jan 30 19:33:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717009, encodeId=f22b1e17009c3, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 03 12:33:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987245, encodeId=f8ba198e245ab, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 15 02:33:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296222, encodeId=dca3129622257, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Apr 05 03:33:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]

相关资讯

SCI REP:中年妇女脉搏波速度与潮热出汗相关!

本研究首次提出baPWV既可以作为中年妇女评价潮热/出汗严重度的客观指标,也可以中年妇女除心血管疾病(CVD)危险因素外动脉僵硬程度预测因子。

Thorax:改良炉灶对妇女和儿童健康有何影响?

厨房是家庭中空气污染最严重的空间。2018年11月,发表在《Thorax》的一项系统评价和Meta分析考查了,改良炉灶对低和中等收入国家妇女和儿童健康的影响。

JAHA:母乳喂养史与绝经后妇女卒中风险

由此可见,该研究的结果显示,在调整多发性卒中危险因素和生活方式变量后,绝经后妇女母乳喂养与卒中风险降低之间存在关联,并且呈剂量反应关系。

在现代营养学里融入中医理念,开展妇女健康教育培训

王宜是中国中医科学院广安门医院食疗营养部主任,从事食疗营养领域工作已经有30余年。她致力于将中医食疗、食养与现代营养学相结合,开创了食疗营养防治体系的先河。同时她也热衷于健康知识的科普工作,足迹遍布学校社区、边远山区和军营哨所,被称为“贴心的营养专家”。

Diabetic Med:妊娠糖尿病妇女的产后经验,知识和认知如何?

近日,国际杂志 《Diabetic Med》上在线发表一项关于妊娠糖尿病妇女的产后经验,知识和认知的研究。 妊娠期糖尿病(GDM)妇女患2型糖尿病的风险增加。这项研究旨在探讨GDM妇女的经验,知识和认知,为预防或延缓2型糖尿病的干预措施提供信息。 研究人员从一家苏格兰健康委员会的诊所招募16名GDM女性,进行半结构式访谈。根据心理学理论(自我调节模型和计划行为理论)提供的主题,使用框架